Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
COVID-19의 대사체/지질체 프로파일링 및 토실리주맙에 대한 개별 반응
Research Article
[키워드] absence
Accuracy
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus-2
affecting
age
age- and sex-matched controls
alteration
Analysis
analyzed
approach
biochemical
caused
change
changes in
characterized
Clinical data
clinical manifestations
Clinical symptoms
Control
control group
controls
coronavirus disease
Coronavirus-2
correlation
correlations
COVID-19
COVID-19 pandemic
COVID-19 patient
COVID-19 patients
determinant
EDTA
evaluated
First wave
Florence
form
global health
Health
heterogeneity
humanized monoclonal antibody
induce
Infection
intensive care treatment
interleukin-6
interleukin-6 receptor
Italy
Magnetic resonance spectroscopy
metabolite
metabolome
metabolomic
metabolomics
MONITOR
NMR-based metabolomic and lipidomic profiling
Novel coronavirus
novel coronavirus disease
nuclear
nuclear magnetic resonance
open
outcomes
pandemic
pathophysiological mechanism
Patient
patients
patients hospitalized
plasma
plasma-EDTA sample
plasma-EDTA samples
provide
recombinant humanized monoclonal antibody
respiratory
response to treatment
SARS-CoV-2
SARS-COV-2 infection
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus-2
small-molecule profile
subset
Symptom
the disease
Tocilizumab
tocilizumab administration
Treatment
treatment with tocilizumab
world population
[DOI] 10.1371/journal.ppat.1009243 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.ppat.1009243 PMC 바로가기 [Article Type] Research Article